New bill would require details on doc payments

The brouhaha over pharmaceutical companies' payments to doctors is making some big waves in Congress. Sen. Charles Grassley (R-IA) says he's going to propose a bill that would require drug makers to 'fess up to any payments for consulting, lectures, and the like. Pharma, of course, is against the measure; a drug company lawyer said that making the cash flow public would lay the money bare to misinterpretation: People might think the payments are bribes, when they're just remuneration for services rendered. Besides, the poor doctors might be too embarrassed to attend those money-for-attendance seminars, thus neglecting their education.

- read the article on the bill from The New York Times

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.